Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) insider Jeffrey Arcara bought 1,003 shares of the business’s stock in a transaction dated Friday, November 13th. The shares were acquired at an average cost of $10.54 per share, for a total transaction of $10,571.62. Following the purchase, the insider owned 4,500 shares of the company’s stock, valued at approximately $47,430. The trade was a 28.68% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Jeffrey Arcara also recently made the following trade(s):
- On Thursday, November 12th, Jeffrey Arcara purchased 497 shares of Corvus Pharmaceuticals stock. The stock was acquired at an average price of $11.12 per share, for a total transaction of $5,526.64.
- On Wednesday, November 11th, Jeffrey Arcara purchased 3,000 shares of Corvus Pharmaceuticals stock. The shares were acquired at an average cost of $11.46 per share, with a total value of $34,380.00.
Corvus Pharmaceuticals Trading Up 0.2%
Shares of CRVS stock traded up $0.02 on Friday, reaching $10.64. 620,431 shares of the company’s stock were exchanged, compared to its average volume of 1,837,983. The company’s fifty day simple moving average is $11.26 and its 200 day simple moving average is $14.10. Corvus Pharmaceuticals, Inc. has a 52 week low of $6.39 and a 52 week high of $26.95. The stock has a market capitalization of $897.48 million, a PE ratio of -14.99 and a beta of 1.57.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, sell-side analysts predict that Corvus Pharmaceuticals, Inc. will post -0.80 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of CRVS. Ancora Advisors LLC increased its holdings in Corvus Pharmaceuticals by 3.6% during the 2nd quarter. Ancora Advisors LLC now owns 56,723 shares of the company’s stock worth $847,000 after purchasing an additional 1,955 shares during the period. Global Retirement Partners LLC bought a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at $30,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Corvus Pharmaceuticals in the 2nd quarter worth $48,000. Avity Investment Management Inc. lifted its holdings in shares of Corvus Pharmaceuticals by 11.9% in the 2nd quarter. Avity Investment Management Inc. now owns 37,150 shares of the company’s stock worth $555,000 after buying an additional 3,950 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter worth $50,000. Institutional investors own 46.64% of the company’s stock.
Recent Corvus Pharmaceuticals Headlines
These are some of the CRVS headlines that stood out recently:
- Positive Sentiment: A Globe and Mail headline includes Corvus among healthcare stocks analysts are bullish on, though the article details provided do not specify a rating or price target. Analysts Are Bullish on Top Healthcare Stocks: Corvus Pharmaceuticals (CRVS), Achieve Life Sciences (QUIT)
- Negative Sentiment: HC Wainwright cut estimates across multiple periods. It now expects a $1.04-per-share loss in 2027, versus its prior $0.80 loss estimate, and a $0.90 loss in 2028, versus $0.37 previously. It also reduced its 2029 forecast from near breakeven to a $0.43 loss and lowered its 2030 profit estimate to $0.45 from $0.67. The revisions suggest a slower improvement in earnings and could weigh on investor sentiment. HC Wainwright earnings estimate updates
Analysts Set New Price Targets
A number of analysts have recently issued reports on CRVS shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, September 16th. Ladenburg Thalmann & Co. Inc. raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. Mizuho set a $27.00 price objective on shares of Corvus Pharmaceuticals in a report on Thursday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research report on Monday, October 26th. Finally, Wall Street Zen cut shares of Corvus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $32.83.
Get Our Latest Research Report on Corvus Pharmaceuticals
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis.
See Also
- Five stocks we like better than Corvus Pharmaceuticals
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
